Previous 10 | Next 10 |
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2023, together w...
Maravai announces plans for William “Trey” Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai’s CEO in July 2023 Carl Hull to continue to serve as Executive Chairman and Inte...
SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it ranked 270 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest...
SOUTHPORT, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cygnus Technologies , part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading assay and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, announced today the lau...
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the months of November and December...
Maravai LifeSciences ( NASDAQ: MRVI ) reached a new 52-week low on Thursday after the company reported a mixed performance with its Q3 2022 results, which prompted Bank of America to downgrade the stock to Neutral from Buy, citing lackluster outlook for 2023. The analy...
Maravai LifeSciences ( NASDAQ: MRVI ) stock fell ~13% premarket on Thursday after the company lowered its FY22 revenue outlook. Q3 Adjusted EPS declined -15.9% Y/Y to $0.37, but beat estimates. Total revenue fell -6.6% Y/Y to $191.26M, missing analysts estima...
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2022 Results Conference Call November 2, 2022 05:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Interim Chief Executive Officer Kevin Herde - Chief Financial Officer Conference C...
Maravai LifeSciences Holdings press release ( NASDAQ: MRVI ): Q3 Non-GAAP EPS of $0.37 beats by $0.04 . Revenue of $191.3M (-6.6% Y/Y) misses by $4.32M . For further details see: Maravai LifeSciences Holdings Non-GAAP EPS of $0.37 beats by $0.04, revenue ...
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2022,...
News, Short Squeeze, Breakout and More Instantly...
Maravai LifeSciences Holdings Inc. Company Name:
MRVI Stock Symbol:
NASDAQ Market:
Maravai LifeSciences Holdings Inc. Website:
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. - Increased the sc...
2024-05-29 15:15:03 ET RBC Capital analyst issues OUTPERFORM recommendation for MRVI on May 29, 2024 01:35PM ET. The previous analyst recommendation was Outperform. MRVI was trading at $8.87 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...